Download Nico Van Zandwijk

Nico van Zandwijk
Head of the Department of Thoracic Oncology,
Netherlands Cancer Institute, Amsterdam, The Netherlands
 Former secretary and chairman of the
European Organisation for Research and
Treatment of Cancer (EORTC) Lung Cancer
Group
 Member of the Board of Directors of the
International Association for the Study of
Lung Cancer (IASLC)
 Member of the Advisory Board of the
Thoracic Section of the French National
Cancer Institute (INCa)
 Is the co-author of more than 180 peer-
reviewed international papers and chapters
 Will take up the post of inaugural director
of a new thoracic oncology institute at the
University of Sydney, Australia, in
March 2008
Netherlands Cancer Institute
Challenges for the first- and
second-line treatment of
non-small cell lung cancer
Nico van Zandwijk
Netherlands Cancer Institute
Amsterdam, The Netherlands
Thursday 7 February 2008
Agenda
14.10 Chair’s opening
Nico van Zandwijk
14.15
The new kid on the block: bevacizumab in first-line NSCLC
Nick Thatcher
14.45
First choice in second line: erlotinib in NSCLC
Romàn Pérez-Soler
15.15
Discussion
15.30
Coffee break
16.00
Meet the Expert sessions
Lung cancer is the most common form of
cancer in the world
Lung
1,352,100
1,151,300
Breast
Bowel
1,023,200
933,900
Stomach
679,000
Prostate
Liver
626,200
493,200
Cervix
Oesophagus
Bladder
Non-Hodgkin’s lymphoma
462,100
356,600
300,600
Leukaemia
Oral cavity
300,500
274,300
Pancreas
Kidney
208,500
Ovary
204,500
Uterus
198,800
Brain and CNS
Melanoma
Larynx
Thyroid
232,300
189,500
160,200
159,000
141,000
Ferlay J, et al. Globocan 2002: Cancer incidence, mortality and prevalence worldwide
Lung cancer has high
incidence and mortality
250,000
Incidence
Estimated new cases/
deaths in the USA (per year)
Mortality
213,380
200,000
180,510
160,390
150,000
112,340
100,000
52,180
50,000
40,910
51,190
37,170
33,370
12,890
0
Breast
Colon
Pancreas
Kidney
Lung
American Cancer Society: cancer facts and figures 2007
Advanced NSCLC: what are the
treatment goals for patients?
 ‘Longer life’
– improved overall survival
 ‘Better life’
– agents for patients who are not suitable for
chemotherapy
– improvement of disease-related symptoms
– better-tolerated regimens; reduced toxicity
– prolonged time to disease progression
– improved disease control rate
– improved quality of life
NSCLC = non-small cell lung cancer
NSCLC: what are the challenges
that we face in the next decade?
 Determine how new agents can be best used in
conjunction with current treatment modalities
 Determine how best to tailor therapy for the patient
 Expanding therapeutic options without increased
toxicity for elderly and performance status 2 patients
 Expanding the eligible patient population for novel
targeted agents
 Treatment options beyond second line